TABLE 1.

Preclinical evaluation of therapeutic strategies targeting TFs and chromatin modifiers in NEPC.

Therapeutic target	Drug	Mechanism of action/effect
EZH2 inhibitors	Tazemetostat, GSK126	Resensitize tumor to AR-signaling inhibitors (Beltran et al., 2016; Clermont et al., 2015)
AURKA inhibitors	Alisertib	Inhibits interaction between NMYC and Aurora-A, suppressing tumor growth (Beltran et al., 2019)
ONECUT2 inhibitor	CSRM617	Reduce proliferation and tumor volume by inducing apoptosis (Choi et al., 2022)
BET inhibitors	MZ1	Degrades BRD4 and controls CRPC metastasis (Shafran et al., 2019)
	JQ1, iBET	Controls CRPC metastasis ((Kim et al., 2021)